Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=169"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=169

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00839800-sae",
        "title": "Symbicort SMART vs Symbicort+Terbutaline As Needed: serious adverse events",
        "summary": "41 of 1049 against 74 of 1042; risk difference -3.2 points, 95% interval -5.2 to -1.2; NCT00839800, Study to Investigate the Efficacy of Symbicort® SMART.",
        "record": "/library/comparisons/NCT00839800-sae",
        "nct_id": "NCT00839800",
        "kind": "serious-adverse-events",
        "participants": 2091,
        "risk_difference": {
          "value": -0.03193243176482858,
          "lower": -0.0519202544611162,
          "upper": -0.01242725397395452
        },
        "group_1": "41 of 1,049",
        "group_2": "74 of 1,042",
        "difference": "-3.2 points",
        "interval": "-5.2 to -1.2",
        "trial_title": "Study to Investigate the Efficacy of Symbicort® SMART."
      },
      {
        "id": "NCT04960202-2ca8d32f",
        "title": "PF-07321332 300 mg + Ritonavir 100 mg vs Placebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)",
        "summary": "228 of 1038 against 256 of 1053; risk difference -2.3 points, 95% interval -6.0 to 1.3; NCT04960202, EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19",
        "record": "/library/comparisons/NCT04960202-2ca8d32f",
        "nct_id": "NCT04960202",
        "kind": "outcome",
        "participants": 2091,
        "risk_difference": {
          "value": -0.023461730590825014,
          "lower": -0.05953172444220046,
          "upper": 0.012710387234683367
        },
        "group_1": "228 of 1,038",
        "group_2": "256 of 1,053",
        "difference": "-2.3 points",
        "interval": "-6.0 to 1.3",
        "trial_title": "EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=170",
  "request_id": "dDa7g8DLVa21FU5L"
}